Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Average Price Target from Analysts
Shares of Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) have earned an average rating of “Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average […]
Shares of Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) have earned an average rating of “Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average […]
